Amphastar Pharmaceuticals Inc
NASDAQ:AMPH

  • LAST PRICE
    44.6400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    42.7000/ 1
  • Ask / Lots
    54.0000/ 1
  • Open / Previous Close
    --- / 44.6400
  • Day Range
    ---
  • 52 Week Range
    36.5600
    65.9249
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 22, 2024

  • Nov 13, 2024

  • Nov 6, 2024

      Show headlines and story abstract

    • 4:14PM ET on Wednesday Nov 06, 2024 by MT Newswires
      Companies Mentioned: AMPH
      04:14 PM EST, 11/06/2024 (MT Newswires) -- ...

    • 4:14PM ET on Wednesday Nov 06, 2024 by MT Newswires
      Companies Mentioned: AMPH
      04:14 PM EST, 11/06/2024 (MT Newswires) -- ...

    • 4:07PM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: AMPH
      Weighted-average shares used to compute adjusted non-GAAP net income per share: Basic 48,621 48,701 48,580 48,368 Diluted 51,862 53,921 52,307 52,997 Three Months Ended September 30, 2024 ------------------------------------------------------------------------------------------ Selling, General Research Non-operating Cost of distribution and and (expenses) Income tax revenue and marketing administrative development income, net provision ------- -------------- ---------------- ------------- --------------- ---------- GAAP $89,273 $ 8,995 $ 14,821 $ 21,077 $ (9,365) $ 7,254 Intangible asset amortization (6,159) - (1) (19) - - Share-based compensation (1,133) (249) (3,710) (504) - - Income tax provision on pre-tax adjustments - - - - - 2,619 ------ ---------- --- ----------- --------- ----------- --------- Non-GAAP $81,981 $ 8,746 $ 11,110 $ 20,554 $ (9,365) $ 9,873 ====== ========== === =========== ========= =========== ========= Three Months Ended September 30, 2023 ------------------------------------------------------------------------------------------ Selling, General Research Non-operating Cost of distribution and and (expenses) Income tax revenue and marketing administrative development income, net provision ------- -------------- ---------------- ------------- --------------- ---------- GAAP $72,153 $ 6,407 $ 12,654 $ 16,664 $ (9,041) $ 14,025 Intangible asset amortization (6,149) - 34 (53) - - Share-based compensation (1,004) (213) (2,975) (452) - - Impairment of long-lived assets (470) - (4) - - - Expenses related to BAQSIMI(R) acquisition - - (357) - 1,825 - Debt issuance costs - - - - 3,019 - Income tax provision on pre-tax adjustments - - - - - 3,811 ------ ---------- --- ----------- --------- ----------- --------- Non-GAAP $64,530 $ 6,194 $ 9,352 $ 16,159 $ (4,197) $ 17,836 ====== ========== === =========== ========= =========== ========= Nine Months Ended September 30, 2024 ------------------------------------------------------------------------------------------- Selling, General Research Non-operating Cost of distribution and and (expenses) Income tax revenue and marketing administrative development income, net provision -------- -------------- ---------------- ------------- --------------- ---------- GAAP $258,237 $ 27,378 $ 43,782 $ 55,772 $ (14,473) $ 23,674 Intangible asset amortization (18,479) - (4) (56) - - Share-based compensation (4,583) (777) (11,239) (2,137) - - Expenses related to BAQSIMI(R) acquisition - - - - 3,651 - Income tax provision on pre-tax adjustments - - - - - 8,912 ------- ---------- --- ----------- --------- ----------- --------- Non-GAAP $235,175 $ 26,601 $ 32,539 $ 53,579 $ (10,822) $ 32,586 ======= ========== === =========== ========= =========== ========= Nine Months Ended September 30, 2023 ------------------------------------------------------------------------------------------- Selling, General Research Non-operating Cost of distribution and and (expenses) Income tax revenue and marketing administrative development income, net provision -------- -------------- ---------------- ------------- --------------- ---------- GAAP $211,309 $ 20,234 $ 38,418 $ 53,322 $ (12,993) $ 27,160 Intangible asset amortization (6,582) - (16) (53) - - Share-based compensation (3,868) (649) (9,323) (1,780) - - Impairment of long-lived assets (3,170) - (4) - - - Expenses related to BAQSIMI(R) acquisition - - (1,857) - 1,825 - Debt issuance costs - - - - 6,043 - Income tax provision on pre-tax adjustments - - - - - 7,725 ------- ---------- --- ----------- --------- ----------- --------- Non-GAAP $197,689 $ 19,585 $ 27,218 $ 51,489 $ (5,125) $ 34,885 ======= ========== === =========== ========= =========== =========

Peers Headlines